AU Patent

AU2016200598A1 — Novel antitumoral use of cabazitaxel

Assigned to Sanofi Mature IP · Expires 2016-02-25 · 10y expired

What this patent protects

NOVEL ANTITUMORAL USE OF CABAZITAXEL AVENTIS PHARMA S.A. Abstract The invention relates to a compound of formula: CH3 0 O CH3 H3 C O H C CH H3C HN , HCH30 which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its u…

USPTO Abstract

NOVEL ANTITUMORAL USE OF CABAZITAXEL AVENTIS PHARMA S.A. Abstract The invention relates to a compound of formula: CH3 0 O CH3 H3 C O H C CH H3C HN , HCH30 which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.

Drugs covered by this patent

Patent Metadata

Patent number
AU2016200598A1
Jurisdiction
AU
Classification
—
Expires
2016-02-25
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi Mature IP
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.